Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR

References

• Stevens WW, Peters AT, Tan BK, et al. Associations between inflammatory endotypes and clinical presentations in chronic rhinosinusitis. J Allergy Clin Immunol Pract. 2019;7(8):2812–2820 e2813. doi:10.1016/j.jaip.2019.05.009
   PubMed Web of Science ®Google Scholar
• Tint D, Kubala S, Toskala E. Risk factors and comorbidities in chronic rhinosinusitis. Curr Allergy Asthma Rep. 2016;16(2):16. doi:10.1007/s11882-015-0589-y
   PubMed Web of Science ®Google Scholar
• Jarvis D, Newson R, Lotvall J, et al. Asthma in adults and its association with chronic rhinosinusitis: the GA2LEN survey in Europe. Allergy. 2012;67(1):91–98. doi:10.1111/j.1398-9995.2011.02709.x
   PubMed Web of Science ®Google Scholar
• Seybt MW, McMains KC, Kountakis SE. The prevalence and effect of asthma on adults with chronic rhinosinusitis. Ear Nose Throat J. 2007;86(7):409–411. doi:10.1177/014556130708600719
   PubMed Web of Science ®Google Scholar
• Canonica GW, Malvezzi L, Blasi F, et al. Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: evidences from the Severe Asthma Network Italy (SANI) registry. Respir Med. 2020;166:105947. doi:10.1016/j.rmed.2020.105947
   PubMed Web of Science ®Google Scholar
• Laidlaw TM, Mullol J, Woessner KM, Amin N, Mannent LP. Chronic rhinosinusitis with nasal polyps and asthma. J Allergy Clin Immunol Pract. 2021;9(3):1133–1141. doi:10.1016/j.jaip.2020.09.063
   PubMed Web of Science ®Google Scholar
• Bachert C, Bhattacharyya N, Desrosiers M, Khan AH. Burden of disease in chronic rhinosinusitis with nasal polyps. J Asthma Allergy. 2021;14:127–134. doi:10.2147/JAA.S290424
   PubMed Web of Science ®Google Scholar
• Vanderhaegen T, Gengler I, Dendooven A, Chenivesse C, Lefèvre G, Mortuaire G. Eosinophils in the field of nasal polyposis: towards a better understanding of biologic therapies. Clin Rev Allergy Immunol. 2022;62(1):90–102. doi:10.1007/s12016-021-08844-7
   PubMed Web of Science ®Google Scholar
• Pearlman AN, Chandra RK, Chang D, et al. Relationships between severity of chronic rhinosinusitis and nasal polyposis, asthma, and atopy. Am J Rhinol Allergy. 2009;23(2):145–148. doi:10.2500/ajra.2009.23.3284
   PubMed Web of Science ®Google Scholar
• Han JK. Subclassification of chronic rhinosinusitis. Laryngoscope. 2013;123 Suppl 2:S15–S27. doi:10.1002/lary.23979
   PubMed Web of Science ®Google Scholar
• Radabaugh JP, Han JK, Moebus RG, Somers E, Lam K. Analysis of histopathological endotyping for chronic rhinosinusitis phenotypes based on comorbid asthma and allergic rhinitis. Am J Rhinol Allergy. 2019;33(5):507–512. doi:10.1177/1945892419846263
   PubMed Web of Science ®Google Scholar
• Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(Suppl S29):1–464. doi:10.4193/Rhin20.600
   Google Scholar
• Du K, Wang M, Zhang N, et al. Involvement of the extracellular matrix proteins periostin and tenascin C in nasal polyp remodeling by regulating the expression of MMPs. Clin Transl Allergy. 2021;11(7):e12059. doi:10.1002/clt2.12059
   PubMed Web of Science ®Google Scholar
• Katainen E, Kostamo K, Virkkula P, et al. Local and systemic proteolytic responses in chronic rhinosinusitis with nasal polyposis and asthma. Int Forum Allergy Rhinol. 2015;5(4):294–302. doi:10.1002/alr.21486
   PubMed Web of Science ®Google Scholar
• Kanemitsu Y, Matsumoto H, Izuhara K, et al. Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids. J Allergy Clin Immunol. 2013;132(2):305–312 e303. doi:10.1016/j.jaci.2013.04.050
   PubMed Web of Science ®Google Scholar
• Håkansson K, Bachert C, Konge L, et al. Airway inflammation in chronic rhinosinusitis with nasal polyps and asthma: the united airways concept further supported. PLoS One. 2015;10(7):e0127228. doi:10.1371/journal.pone.0127228
   PubMed Web of Science ®Google Scholar
• Chaaban MR, Walsh EM, Woodworth BA. Epidemiology and differential diagnosis of nasal polyps. Am J Rhinol Allergy. 2013;27(6):473–478. doi:10.2500/ajra.2013.27.3981
   PubMed Web of Science ®Google Scholar
• Wang M, Bu X, Luan G, et al. Distinct type 2-high inflammation associated molecular signatures of chronic rhinosinusitis with nasal polyps with comorbid asthma. Clin Transl Allergy. 2020;10(1):26. doi:10.1186/s13601-020-00332-z
   PubMed Web of Science ®Google Scholar
• Yan B, Lou H, Wang Y, et al. Epithelium-derived cystatin SN enhances eosinophil activation and infiltration through IL-5 in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2019;144(2):455–469. doi:10.1016/j.jaci.2019.03.026
   PubMed Web of Science ®Google Scholar
• Ediger D, Sin BA, Heper A, Anadolu Y, Misirligil Z. Airway inflammation in nasal polyposis: immunopathological aspects of relation to asthma. Clin Exp Allergy. 2005;35(3):319–326. doi:10.1111/j.1365-2222.2005.02194.x
   PubMed Web of Science ®Google Scholar
• Canonica GW, Harrison TW, Chanez P, et al. Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis. Allergy. 2022;77(1):150–161. doi:10.1111/all.14902
   PubMed Web of Science ®Google Scholar
• Tiotiu A, Oster JP, Roux PR, et al. Effectiveness of omalizumab in severe allergic asthma and nasal polyposis: a real-life study. J Investig Allergol Clin Immunol. 2020;30(1):49–57. doi:10.18176/jiaci.0391
   PubMed Web of Science ®Google Scholar
• Harrison TW, Chanez P, Menzella F, et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respir Med. 2021;9(3):260–274. doi:10.1016/S2213-2600(20)30414-8
   PubMed Web of Science ®Google Scholar
• Howarth P, Chupp G, Nelsen LM, et al. Severe eosinophilic asthma with nasal polyposis: a phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy. J Allergy Clin Immunol. 2020;145(6):1713–1715. doi:10.1016/j.jaci.2020.02.002
   PubMed Web of Science ®Google Scholar
• Nolasco S, Crimi C, Pelaia C, et al. Benralizumab effectiveness in severe eosinophilic asthma with and without chronic rhinosinusitis with nasal polyps: a real-world multicenter study. J Allergy Clin Immunol Pract. 2021;9(12):4371–4380 e4374. doi:10.1016/j.jaip.2021.08.004
   PubMed Web of Science ®Google Scholar
• Bagnasco D, Brussino L, Bonavia M, et al. Efficacy of benralizumab in severe asthma in real life and focus on nasal polyposis. Respir Med. 2020;171:106080. doi:10.1016/j.rmed.2020.106080
   PubMed Web of Science ®Google Scholar
• Hopkins C, Buchheit KM, Heffler E, et al. Improvement in health-related quality of life with dupilumab in patients with moderate-to-severe asthma with comorbid chronic rhinosinusitis with/without nasal polyps: an analysis of the QUEST study. J Asthma Allergy. 2022;15:767–773. doi:10.2147/JAA.S363527
   PubMed Web of Science ®Google Scholar
• Berger P, Menzies-Gow A, Peters AT, et al. Long-term efficacy of dupilumab in asthma with or without chronic rhinosinusitis and nasal polyps. Ann Allergy Asthma Immunol. 2023;130(2):215–224. doi:10.1016/j.anai.2022.11.006
   PubMed Web of Science ®Google Scholar
• Gallo S, Castelnuovo P, Spirito L, et al. Mepolizumab improves outcomes of chronic rhinosinusitis with nasal polyps in severe asthmatic patients: a multicentric real-life study. J Pers Med. 2022;12(8):1304. doi:10.3390/jpm12081304
   PubMed Web of Science ®Google Scholar
• Laidlaw TM, Bachert C, Amin N, et al. Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma. Ann Allergy Asthma Immunol. 2021;126(5):584–592 e581. doi:10.1016/j.anai.2021.01.012
   PubMed Web of Science ®Google Scholar
• Kavanagh JE, d’Ancona G, Elstad M, et al. Real-world effectiveness and the characteristics of a “super-responder” to mepolizumab in severe eosinophilic asthma. Chest. 2020;158(2):491–500. doi:10.1016/j.chest.2020.03.042
   PubMed Web of Science ®Google Scholar
• Eger K, Kroes JA, Ten Brinke A, Bel EH. Long-term therapy response to anti-IL-5 biologics in severe asthma - a real-life evaluation. J Allergy Clin Immunol Pract. 2021;9(3):1194–1200. doi:10.1016/j.jaip.2020.10.010
   PubMed Web of Science ®Google Scholar
• Harvey ES, Langton D, Katelaris C, et al. Mepolizumab effectiveness and identification of super-responders in severe asthma. Eur Respir J. 2020;55(5):1902420. doi:10.1183/13993003.02420-2019
   PubMed Web of Science ®Google Scholar
• Laidlaw TM, Prussin C, Panettieri RA, et al. Dexpramipexole depletes blood and tissue eosinophils in nasal polyps with no change in polyp size. Laryngoscope. 2019;129(2):E61–E66. doi:10.1002/lary.27564
   PubMed Web of Science ®Google Scholar
• Ahern S, Cervin A. Inflammation and endotyping in chronic rhinosinusitis - a paradigm shift. Medicina. 2019;55(4):95. doi:10.3390/medicina55040095
   PubMedGoogle Scholar
• Ebina-Shibuya R, Leonard WJ. Role of thymic stromal lymphopoietin in allergy and beyond. Nat Rev Immunol. 2022;23:24–37. doi:10.1038/s41577-022-00735-y
   PubMed Web of Science ®Google Scholar
• Varricchi G, Pecoraro A, Marone G, et al. Thymic stromal lymphopoietin isoforms, inflammatory disorders, and cancer. Front Immunol. 2018;9:1595. doi:10.3389/fimmu.2018.01595
   PubMed Web of Science ®Google Scholar
• Klimek L, Hagemann J, Welkoborsky HJ, et al. Epithelial immune regulation of inflammatory airway diseases: chronic rhinosinusitis with nasal polyps (CRSwNP). Allergol Select. 2022;6:148–166. doi:10.5414/alx02296e
   PubMedGoogle Scholar
• Allakhverdi Z, Comeau MR, Jessup HK, et al. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J Exp Med. 2007;204(2):253–258. doi:10.1084/jem.20062211
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777–792. doi:10.1080/14728222.2020.1783242
   PubMed Web of Science ®Google Scholar
• Golebski K, van Tongeren J, van Egmond D, de Groot EJ, Fokkens WJ, van Drunen CM. Specific induction of TSLP by the viral RNA analogue poly(I:C) in primary epithelial cells derived from nasal polyps. PLoS One. 2016;11(4):e0152808. doi:10.1371/journal.pone.0152808
   PubMed Web of Science ®Google Scholar
• Lan F, Zhang N, Holtappels G, et al. Staphylococcus aureus induces a Th2 response via TSLP and IL-33 release in human airway mucosa. J Allergy Clin Immunol. 2015;135(2):AB81. doi:10.1016/j.jaci.2014.12.1196
   Web of Science ®Google Scholar
• Hui CC, Yu A, Heroux D, et al. Thymic stromal lymphopoietin (TSLP) secretion from human nasal epithelium is a function of TSLP genotype. Mucosal Immunol. 2015;8(5):993–999. doi:10.1038/mi.2014.126
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang X, Zhang W, Han D, Zhang L, Bachert C. Polymorphisms in thymic stromal lymphopoietin gene demonstrate a gender and nasal polyposis-dependent association with chronic rhinosinusitis. Hum Immunol. 2013;74(2):241–248. doi:10.1016/j.humimm.2012.11.004
   PubMed Web of Science ®Google Scholar
• Nakayama T, Hirota T, Asaka D, et al. A genetic variant near TSLP is associated with chronic rhinosinusitis with nasal polyps and aspirin-exacerbated respiratory disease in Japanese populations. Allergol Int. 2020;69(1):138–140. doi:10.1016/j.alit.2019.06.007
   PubMed Web of Science ®Google Scholar
• Dogan M, Sahin M, Yenisey C. Increased TSLP, IL-33, IL-25, IL-19, IL 21 and amphiregulin (AREG) levels in chronic rhinosinusitis with nasal polyp. Eur Arch Otorhinolaryngol. 2019;276(6):1685–1691. doi:10.1007/s00405-019-05379-8
   PubMed Web of Science ®Google Scholar
• Kimura S, Pawankar R, Mori S, et al. Increased expression and role of thymic stromal lymphopoietin in nasal polyposis. Allergy Asthma Immunol Res. 2011;3(3):186–193. doi:10.4168/aair.2011.3.3.186
   PubMed Web of Science ®Google Scholar
• Nagarkar DR, Poposki JA, Tan BK, et al. Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2013;132(3):593–600.e512. doi:10.1016/j.jaci.2013.04.005
   PubMed Web of Science ®Google Scholar
• Ogasawara N, Klingler AI, Tan BK, et al. Epithelial activators of type 2 inflammation: elevation of thymic stromal lymphopoietin, but not IL-25 or IL-33, in chronic rhinosinusitis with nasal polyps in Chicago, Illinois. Allergy. 2018;73(11):2251–2254. doi:10.1111/all.13552
   PubMed Web of Science ®Google Scholar
• Ouyang Y, Fan E, Li Y, Wang X, Zhang L. Clinical characteristics and expression of thymic stromal lymphopoetin in eosinophilic and non-eosinophilic chronic rhinosinusitis. ORL J Otorhinolaryngol Relat Spec. 2013;75(1):37–45. doi:10.1159/000346929
   PubMed Web of Science ®Google Scholar
• Cao P, Wang BF, Zhang Y, et al. TSLP signaling and TH2-type inflammation is enhanced in eosinophilic but not noneosinophilic nasal polyps. J Allergy Clin Immunol. 2011;127(2):AB140. doi:10.1016/j.jaci.2010.12.557
   Web of Science ®Google Scholar
• Kato A, Poposki JA, Nagarkar DR, et al. Role of thymic stromal lymphopoietin (TSLP) in chronic rhinosinusitis. J Allergy Clin Immunol. 2012;129(2):AB70. doi:10.1016/j.jaci.2011.12.755
   Web of Science ®Google Scholar
• Poposki JA, Klingler AI, Stevens WW, et al. Proprotein convertases generate a highly functional heterodimeric form of thymic stromal lymphopoietin in humans. J Allergy Clin Immunol. 2017;139(5):1559–1567.e1558. doi:10.1016/j.jaci.2016.08.040
   PubMed Web of Science ®Google Scholar
• Kato A, Schleimer RP, Bleier BS. Mechanisms and pathogenesis of chronic rhinosinusitis. J Allergy Clin Immunol. 2022;149(5):1491–1503. doi:10.1016/j.jaci.2022.02.016
   PubMed Web of Science ®Google Scholar
• Cao PP, Zhang YN, Liao B, et al. Increased local IgE production induced by common aeroallergens and phenotypic alteration of mast cells in Chinese eosinophilic, but not non-eosinophilic, chronic rhinosinusitis with nasal polyps. Clin Exp Allergy. 2014;44(5):690–700. doi:10.1111/cea.12304
   PubMed Web of Science ®Google Scholar
• Dwyer DF, Ordovas-Montanes J, Allon SJ, et al. Human airway mast cells proliferate and acquire distinct inflammation-driven phenotypes during type 2 inflammation. Sci Immunol. 2021;6(56):eabb7221. doi:10.1126/sciimmunol.abb7221
   PubMed Web of Science ®Google Scholar
• Buchheit KM, Cahill KN, Katz HR, et al. Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2016;137(5):1566–1576.e1565. doi:10.1016/j.jaci.2015.10.020
   PubMed Web of Science ®Google Scholar
• Braile M, Fiorelli A, Sorriento D, et al. Human lung-resident macrophages express and are targets of thymic stromal lymphopoietin in the tumor microenvironment. Cells. 2021;10(8):2012. doi:10.3390/cells10082012
   PubMed Web of Science ®Google Scholar
• Wong CK, Hu S, Cheung PFY, Lam CWK. Thymic stromal lymphopoietin induces chemotactic and prosurvival effects in eosinophils: implications in allergic inflammation. Am J Respir Cell Mol Biol. 2010;43(3):305–315. doi:10.1165/rcmb.2009-0168OC
   PubMed Web of Science ®Google Scholar
• Kato Y, Takabayashi T, Sakashita M, et al. Expression and functional analysis of CST1 in intractable nasal polyps. Am J Respir Cell Mol Biol. 2018;59(4):448–457. doi:10.1165/rcmb.2017-0325OC
   PubMed Web of Science ®Google Scholar
• Nocera AL, Mueller SK, Workman AD, et al. Cystatin SN is a potent upstream initiator of epithelial-derived type 2 inflammation in chronic rhinosinusitis. J Allergy Clin Immunol. 2022;150(4):872–881. doi:10.1016/j.jaci.2022.04.034
   PubMed Web of Science ®Google Scholar
• Wang WW, Lu DM, Zheng M, Zhang JG, Zhang B. TSLP regulates eotaxin-1 production by nasal epithelial cells from patients with eosinophilic CRSwNP. Rhinology. 2018;56(4):370–377. doi:10.4193/Rhin17.045
   PubMed Web of Science ®Google Scholar
• Poposki JA, Klingler AI, Tan BK, et al. Group 2 innate lymphoid cells are elevated and activated in chronic rhinosinusitis with nasal polyps. Immun Inflamm Dis. 2017;5(3):233–243. doi:10.1002/iid3.161
   PubMed Web of Science ®Google Scholar
• Gevaert E, Delemarre T, De Volder J, et al. Charcot-Leyden crystals promote neutrophilic inflammation in patients with nasal polyposis. J Allergy Clin Immunol. 2020;145(1):427–430.e424. doi:10.1016/j.jaci.2019.08.027
   PubMed Web of Science ®Google Scholar
• Persson EK, Verstraete K, Heyndrickx I, et al. Protein crystallization promotes type 2 immunity and is reversible by antibody treatment. Science. 2019;364(6442):eaaw4295. doi:10.1126/science.aaw4295
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, O’Byrne PM, Boulet LP, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014;370(22):2102–2110. doi:10.1056/NEJMoa1402895
   PubMed Web of Science ®Google Scholar
• Marone G, Spadaro G, Braile M, et al. Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma. Expert Opin Investig Drugs. 2019;28(11):931–940. doi:10.1080/13543784.2019.1672657
   PubMedGoogle Scholar
• Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936–946. doi:10.1056/NEJMoa1704064
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800–1809. doi:10.1056/NEJMoa2034975
   PubMed Web of Science ®Google Scholar
• Corren J, Pham TH, Garcia Gil E, et al. Baseline type 2 biomarker levels and response to tezepelumab in severe asthma. Allergy. 2022;77(6):1786–1796. doi:10.1111/all.15197
   PubMed Web of Science ®Google Scholar
• Diver S, Khalfaoui L, Emson C, et al. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299–1312. doi:10.1016/S2213-2600(21)00226-5
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov (NCT02573233). Evaluation of dupilumab’s effects on airway inflammation in patients with asthma (EXPEDITION). Available from: https://clinicaltrials.gov/ct2/show/study/NCT02573233. Accessed July 05, 2023.
   Google Scholar
• Emson C, Corren J, Sałapa K, Hellqvist Å, Parnes JR, Colice G. Efficacy of tezepelumab in patients with severe, uncontrolled asthma with and without nasal polyposis: a post hoc analysis of the phase 2b PATHWAY study. J Asthma Allergy. 2021;14:91–99. doi:10.2147/jaa.S288260
   PubMed Web of Science ®Google Scholar
• Tepper RS, Wise RS, Covar R, et al. Asthma outcomes: pulmonary physiology. J Allergy Clin Immunol. 2012;129(3 Suppl):S65–S87. doi:10.1016/j.jaci.2011.12.986
   PubMed Web of Science ®Google Scholar
• Asthma Control Questionnaire. American thoracic society. Available from: http://www.thoracic.org/members/assemblies/assemblies/srn/questionaires/acq.php. Accessed July 05, 2023.
   Google Scholar
• Juniper EF, Buist AS, Cox FM, Ferrie PJ, King DR. Validation of a standardized version of the asthma quality of life questionnaire. Chest. 1999;115(5):1265–1270. doi:10.1378/chest.115.5.1265
   PubMed Web of Science ®Google Scholar
• Globe G, Wiklund I, Mattera M, Zhang H, Revicki DA. Evaluating minimal important differences and responder definitions for the asthma symptom diary in patients with moderate to severe asthma. J Patient Rep Outcomes. 2019;3(1):22. doi:10.1186/s41687-019-0109-2
   PubMedGoogle Scholar
• Chowdhury NI, Mace JC, Bodner TE, et al. Investigating the minimal clinically important difference for SNOT-22 symptom domains in surgically managed chronic rhinosinusitis. Int Forum Allergy Rhinol. 2017;7(12):1149–1155. doi:10.1002/alr.22028
   PubMed Web of Science ®Google Scholar
• Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychometric validity of the 22-item sinonasal outcome test. Clin Otolaryngol. 2009;34(5):447–454. doi:10.1111/j.1749-4486.2009.01995.x
   PubMed Web of Science ®Google Scholar
• Pham T, Kearley J, Parnes JR, Leung D, Goleva E, Griffiths J. Development of a highly sensitive assay to quantitate circulating thymic stromal lymphopoietin (TSLP) levels in blood. J Allergy Clin Immunol. 2020;145(2):AB30. doi:10.1016/j.jaci.2019.12.820
   Web of Science ®Google Scholar
• Khan AH, Reaney M, Guillemin I, et al. Development of Sinonasal Outcome Test (SNOT-22) domains in chronic rhinosinusitis with nasal polyps. Laryngoscope. 2022;132(5):933–941. doi:10.1002/lary.29766
   PubMed Web of Science ®Google Scholar
• Busse W, Maspero JF, Katelaris CH, et al. Dupilumab improves SNOT-22 scores in asthma patients with chronic rhinosinusitis or nasal polypsosis (CRS/NP) in LIBERTY ASTHMA QUEST. Eur Resp J. 2018;52:PA1125. doi:10.1183/13993003.congress-2018.PA1125
   Web of Science ®Google Scholar
• Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146(3):595–605. doi:10.1016/j.jaci.2020.05.032
   PubMed Web of Science ®Google Scholar
• Busse WW, Wellman A, Diamant Z, et al. Impact of dupilumab on SNOT-22 sleep and function scores in CRSwNP. J Allergy Clin Immunol Pract. 2022;10(9):2479–2482 e2473. doi:10.1016/j.jaip.2022.05.013
   PubMed Web of Science ®Google Scholar
• Pelaia C, Paoletti G, Puggioni F, et al. Interleukin-5 in the pathophysiology of severe asthma. Front Physiol. 2019;10:1514. doi:10.3389/fphys.2019.01514
   PubMed Web of Science ®Google Scholar
• Bagnasco D, Ferrando M, Varricchi G, Passalacqua G, Canonica GW. A critical evaluation of anti-IL-13 and anti-IL-4 strategies in severe asthma. Int Arch Allergy Immunol. 2016;170(2):122–131. doi:10.1159/000447692
   PubMed Web of Science ®Google Scholar
• Bickel M. The role of interleukin-8 in inflammation and mechanisms of regulation. J Periodontol. 1993;64(5 Suppl):456–460.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang N, Bo M, et al. Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: a multicenter study in Europe, Asia, and Oceania. J Allergy Clin Immunol. 2016;138(5):1344–1353. doi:10.1016/j.jaci.2016.05.041
   PubMed Web of Science ®Google Scholar
• Jain N, Siri D, Yancey S, Price R, Wenzel S. Mepolizumab reduces exacerbations and improves health-related quality of life in patients with severe asthma and nasal polyps, sinusitis, or allergic rhinitis. J Allergy Clin Immunol. 2020;145(2):AB26. doi:10.1016/j.jaci.2019.12.808
   Web of Science ®Google Scholar
• Maspero JF, Katelaris CH, Busse WW, et al. Dupilumab efficacy in uncontrolled, moderate-to-severe asthma with self-reported chronic rhinosinusitis. J Allergy Clin Immunol Pract. 2020;8(2):527–539 e529. doi:10.1016/j.jaip.2019.07.016
   PubMed Web of Science ®Google Scholar